TP53 mutations and treatment outcome in CLL

Kaplan-Meier estimates of progression-free survival (A) and overall survival (B) according to TP53 mutation status in patients with chronic lymphocytic leukemia (CLL) initially treated with fludarabine, cyclophosphamide, and rituximab.

FCR: fludarabine, cyclophosphamide, and rituximab; PFS: progression-free survival; OS: overall survival; TP53^WT: wild-type TP53; TP53^mut: mutant TP53.

This research was originally published in Blood. Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014; 123:3247. Copyright © 2014 American Society of Hematology.

Graphic 108430 Version 1.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟